|By Marketwired .||
|March 11, 2014 05:00 PM EDT||
AURORA, ON -- (Marketwired) -- 03/11/14 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Sylwester Cacek is currently president of Sfinks Polska SA, and was the founder of Dominet Capital Group, which included a nationwide retail bank Dominet Bank SA. As CEO of the group, Mr. Cacek created a nationwide financial institution with a wide range of products and services dedicated to individual clients and small and medium enterprises. In 2007, Dominet SA was successfully sold to Fortis Group. In his career, Mr. Cacek has served as a member of supervisory boards in such companies as Dominet Bank SA, Impel SA, OrsNet Sp. z o.o., SportLive24 SA and KS Widzew Łódź SA. He is a shareholder of the Polish professional football club RTS Widzew Łódź. Mr. Cacek currently holds or exercises control or direction over, directly or indirectly, 6,934,400 common shares of Helix.
Commenting on the appointment, Robert Verhagen, President and CEO, said, "Mr. Cacek has many years of experience in the financial sectors and, with his insight into business management, I look forward to the insights he will bring to our board and to working with him as Helix pursues its growth initiatives."
Mr. Cacek's appointment comes after the board received and accepted Mr. Slawomir Ludwikowski's resignation from the board of directors. A majority of the votes represented by proxy at Helix's annual general and special meeting of shareholders held on December 18, 2013 were withheld from voting for Mr. Ludwikowski and, in accordance with Helix's majority voting policy, Mr. Ludwikowski was required to submit his resignation to the board of directors for its consideration.
Helix also announced that Mr. Andreas Kandziora has been asked to act as an Observer to the board of directors, effective March 7, 2014. Mr. Kandziora is President and CEO of Liechtenstein-based financial advisory and business consulting firm ACM Alpha Consulting Management Est. He has experience in the fields of corporate development, project management and financing, marketing, and consulting.
Mr. Verhagen commented, "Mr. Kandziora has worked with Helix since 2007 as a vital link to our European shareholders. His status as Observer will greatly increase our ability to communicate the direction of the company to these shareholders effectively."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and Uncertainties
This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the increase in the ability of Helix to communicate effectively with its European shareholders following Mr. Kandzioras's appointment as an observer to the board of directors. Forward-looking statements, which may be identified by words including, without limitation, "will", and other similar expressions, are intended to provide information about management's current plans and expectations regarding the operations of Helix.
Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.
Helix BioPharma Corp.
Tel: 905 841-2300
Email: [email protected]